首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   163125篇
  免费   14811篇
  国内免费   6846篇
耳鼻咽喉   2265篇
儿科学   3717篇
妇产科学   1802篇
基础医学   29564篇
口腔科学   5167篇
临床医学   12424篇
内科学   22108篇
皮肤病学   4350篇
神经病学   9099篇
特种医学   3600篇
外国民族医学   118篇
外科学   14227篇
综合类   25538篇
预防医学   4236篇
眼科学   3412篇
药学   12550篇
  26篇
中国医学   5070篇
肿瘤学   25509篇
  2024年   52篇
  2023年   2304篇
  2022年   2910篇
  2021年   5034篇
  2020年   5330篇
  2019年   4927篇
  2018年   5017篇
  2017年   5571篇
  2016年   5645篇
  2015年   6296篇
  2014年   9544篇
  2013年   10484篇
  2012年   9388篇
  2011年   10619篇
  2010年   8795篇
  2009年   8462篇
  2008年   8925篇
  2007年   9152篇
  2006年   8331篇
  2005年   7652篇
  2004年   6777篇
  2003年   5858篇
  2002年   4807篇
  2001年   4115篇
  2000年   3390篇
  1999年   2944篇
  1998年   2426篇
  1997年   2367篇
  1996年   2048篇
  1995年   2070篇
  1994年   1830篇
  1993年   1525篇
  1992年   1233篇
  1991年   1170篇
  1990年   897篇
  1989年   846篇
  1988年   787篇
  1987年   626篇
  1986年   585篇
  1985年   777篇
  1984年   688篇
  1983年   482篇
  1982年   507篇
  1981年   403篇
  1980年   341篇
  1979年   254篇
  1978年   178篇
  1977年   138篇
  1976年   103篇
  1975年   39篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
肾脏是人体最重要的排泄器官。肾单元近端小管细胞具有多种药物转运体和代谢酶,在药物及其代谢物处置中发挥关键作用。近端小管细胞中主要转运体包括有机阴离子转运体、有机阳离子转运体、有机阳离子/肉毒碱转运体、多药及毒素外排转运蛋白、P-糖蛋白、乳腺癌耐药蛋白和多药耐药相关蛋白;主要代谢酶包括细胞色素P450酶,UDP-葡萄糖醛酸基转移酶、磺酸基转移酶、谷胱甘肽S-转移酶。肾脏转运体和/或代谢酶介导药物相互作用(DDIs)是临床关注的重要问题。肾脏转运体和代谢酶存在密切协作关系,在肾脏也存在多种相互作用现象(包括转运-转运相互作用,代谢-代谢相互作用和转运-代谢相互作用),其显著影响药物肾脏处置、临床疗效和肾毒性。本文系统阐述了这些相互作用对药物及其代谢物的肾脏排泄、药动学、DDIs和肾毒性的影响。今后需要进一步阐明肾脏转运-代谢相互作用机制,将有助于研究体内药物肾脏处置和DDIs,促进临床合理用药。  相似文献   
2.
3.
4.
Since their inception in the 1960s–70s, mesenchymal stem/stromal cells (MSCs) have gained interest because of their differentiation potential, anti-inflammatory effects, and immune-modulating properties. Both cell-based and cell-free MSC treatments show healing capacity in injured tissues. Cell-based treatment comprises MSCs and all secreted products, whereas cell-free treatments include only the secreted products. MSCs are therapeutically administered to many damaged organs owing to their efficacy. Specifically, the eye is a unique organ system to study the effects of MSCs, as treatment is easily applied and measured owing to its external location. The eye holds an immune-privileged status, wherein inflammation and immune responses are innately down-regulated. As excessive inflammation in the cornea often leads to fibrosis and irreversible corneal hazing, many studies have investigated the anti-inflammatory and immune-modulating capacities of MSCs. Decades of research suggest that MSCs modulate the immune response by secreting cytokines, growth factors, and extracellular matrix proteins that inhibit the infiltration of inflammatory cells following injury and promote a healing phenotype via M2 macrophage polarization. MSCs have also shown trans-differentiation potential into cornea-specific cell types during the wound healing process, such as corneal epithelial, stromal, or endothelial cells. This review discusses recent investigations of MSC treatment in the cornea, focusing on therapeutic efficacy, mechanisms, and future directions.  相似文献   
5.
6.
《Clinical lung cancer》2022,23(6):467-476
BackgroundImmune checkpoint inhibitor (ICI) monotherapy is more effective than cytotoxic chemotherapy in improving overall survival (OS) among patients with advanced-stage non-small cell lung cancer (NSCLC). Recently, chemotherapy combined with ICI has been found to yield good outcomes. However, ICI monotherapy is still considered an important treatment option. Data on long-term progression-free survival (PFS) and OS in real-world settings are limited.Patients and MethodsThis was a multicenter retrospective observational study. A total of 435 consecutive patients histologically diagnosed with advanced, metastatic, or recurrent NSCLC treated with ICI monotherapy were enrolled in this study from December 2015 to December 2018. Clinical data were collected from electronic medical records and pharmacy databases.ResultsThe PFS and OS of the patients were 3.4 and 13.0 months, respectively. The objective response and disease control rates were 22.8% and 54.9%, respectively, and the 4-year survival rate was 17.9%. Multivariate analyses revealed that elder patients (>70 years), good Eastern Cooperative Oncology Group Performance Status (ECOG PS) score, programmed death-ligand 1 tumor proportion score (PD-L1 TPS) of ≥ 50%, absence of bone metastasis, and presence of immune-related skin toxicity, which is an immune-related adverse event, were correlated with good PFS. Moreover, good ECOG PS score, PD-L1 TPS of ≥ 50%, absence of bone metastasis, and presence of skin toxicity were correlated with good OS.ConclusionsThe 4-year survival rate was 17.9%. Good ECOG PS score, PD-L1 TPS of ≥ 50%, absence of bone metastasis, and presence of skin toxicity were correlated with good PFS and OS.  相似文献   
7.
《Cancer cell》2022,40(11):1392-1406.e7
  1. Download : Download high-res image (241KB)
  2. Download : Download full-size image
  相似文献   
8.
BackgroundSurgical resection is recommended for patients with resectable acinar cell carcinoma (ACC). The aim of this study was to investigate the clinical characteristics and surgical outcomes of resectable ACC in comparison to pancreatic ductal adenocarcinoma (PDAC).MethodA retrospective analysis was performed on all patients who consecutively underwent radical resection with pathologically confirmed ACC and PDAC from December 2011 to December 2018. Clinicopathologic characteristics and follow-up information were analyzed. A 1:3 propensity score matching (PSM) method was used to minimize the bias between ACC and PDAC.ResultsA total of 26 patients with ACC and 1351 with PDAC were included. Compared to PDAC, ACC tended to be larger (4.5 vs. 3.0 cm; p < 0.001) and more frequently located in the pancreatic body/tail (61.5% vs. 36.6%, p = 0.009), with lower total bilirubin levels, lower neutrophil lymphocyte ratio (NLR) levels and lower carbohydrate antigen 19-9 (CA19-9) levels and carcinoembryonic antigen (CEA) levels. There was no difference in postoperative morbidities in patients with ACC and PDAC. The median OS and RFS were longer in ACC when compared to PDAC (OS: 43.5 mo vs. 19.0 mo, p = 0.004; RFS: 24.5 mo vs. 11.6 mo, p = 0.023). After the 1:3 PSM, ACC remained to be a better histological type for OS (p = 0.024), but had comparable RFS with PDAC (p = 0.164).ConclusionPatients with ACC after radical resection had better OS than that with PDAC. However, ACC is also an aggressive tumor with a similar trend of RFS with PDAC after the matching, necessitating the multidisciplinary treatment for resectable ACC disease.  相似文献   
9.
口腔鳞状细胞癌(oral squamous cell carcinoma,OSCC)的发病率和死亡率呈年轻化趋势上升,已成为世界范围内的主要公共卫生问题。近年来,慢性牙周炎(chronic periodontitis,CP)与口腔鳞癌之间的关系越来越受到重视,一些研究发现,以慢性炎症和微生物失调为特征的牙周病是口腔肿瘤发生的重要危险因素。本文就慢性牙周炎与口腔鳞癌的相关研究,牙周主要致病菌、细胞因子、NF-κB等在两者中的桥梁作用,以及抗炎药物在口腔鳞癌中的应用做主要阐述。  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号